Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLIgAN personalized therapy study in immunoglobulin A nephropathy
2021-006854-29Phase 3Active
- Sponsor
- Fondazione Schena
- Start
- Mar 2022
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of prednisone, methylprednisolone sodium succinate and dapagliflozin in IgA nephropathy (IgAN) (3 arms), sponsored by Fondazione Schena. Primary endpoint: Between-arm difference in proteinuria reduction. Started Mar 2022; status: active.
02
Drugs
prednisonemethylprednisolone sodium succinatedapagliflozin
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on 2021-006854-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006854-29.